Pharmacy & Therapeutics - April 2008 - (Page 219) DRUG FORECAST provides several advantages to orally administered MAOIs, including freedom from dietary tyramine modifications at a dose of 6 mg/24 hours and a favorable side-effect profile. Given their positions in the pathway of care, pharmacists and physicians play a major role in counseling patients about the potential for drug interactions and alternative treatments. Accordingly, awareness of potential interactions that may be encountered with the STS will optimize the use of this MAOI as an alternative for patients with MDD. Acknowledgments: Shahid Salaria, PhD, of Medicus International provided editorial support. 16. elzine in melancholias and dysthymic disorders. Br J Psychiatry 1987; 151:639– 642. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractor y depression. Am J Psychiatry 1993;150(1):118–123. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149(2):195–198. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression, II. MAO inhibitors in depression resistant to cyclic antidepressants: Two controlled crossover studies with tranylcypromine versus L-5-hydroxytr yptophan and nomifensine. Acta Psychiatr Scand 1988;78(6): 676–683. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin Nor th Am 1996;19(2):371–386. Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatmentresistant depression: A retrospective study. J Affect Disord 2005;89(1–3):183– 188. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148(7):910–916. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12(3):185–219. Blackwell B, Marley E, Price J, et al. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967;113:349–365. Robinson DS. Monoamine oxidase inhibitors: A new generation. Gen Psycho pharmacol 2002;36(3):124–138. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: A doubleblind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002;159(11):1869–1875. Feiger AD, Rickels K, Zimbroff DL, et al. Selegiline transdermal system for the treatment of major depressive disorder: An eight-week, double-blind, placebocontrolled, flexible-dose titration trial. J Clin Psychiatry 2006;67:1354–1361. Amsterdam JA. Double-blind, placebocontrolled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003;64(2):208–214. Amsterdam JD, Bodkin JA. Selegiline Transdermal System (STS) in the prevention of relapse of major depressive disorder: A 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006; 26(6):579–586. Emsam (Selegiline Transdermal System), prescribing information. Available at: www.bms.com. Accessed September 2006. Mallinger AG, Smith E. Pharmaco kinetics of monoamine oxidase inhibitors. Psychopharmacol Bull 1991;27(4): 493–502. Baker GB, Urichuk LJ, McKenna KF, et al. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 1999;19(3): 411–426. Isbister GK, Buckley NA, White IM. Serotonin toxicity: A practical approach to diagnosis and treatment. Med J Austral 2007;187(6):361–365. Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988; 2(8615):850–851. Kline SS, Mauro LS, Scala-Barnett DM, et al. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm 1989;8(7):510–514. Ooi A, Mai M, Ogino T, et al. Endocrine differentiation of gastric adenocarcinoma: The prevalence as evaluated by immunoreactive chromogranin A and its biologic significance. Cancer 1988;62(6): 1096–1104. Heisler MA, Guidry JR, Arnecke B. Serotonin syndrome induced by administration of venlafaxine and phenelzine. Ann Pharmacother 1996;30(1):84. Klysner R, Larsen JK, Sorensen P, et al. Toxic interaction of venlafaxine and isocarboxazide. Lancet 1995;346(8985): 1298–1299. Phillips SD, Ringo P. Phenelzine and venlafaxine interaction. Am J Psychiatry 1995; 152(9):1400–1401. Weiner LA, Smythe M, Cisek J. Serotonin syndrome secondary to phenelzine– venlafaxine interaction. Pharmacotherapy 1998;18(2):399–403. Beasley CM Jr, Masica DN, Heiligenstein JH, et al. Possible monoamine oxidase inhibitor–serotonin uptake inhibitor interaction: Fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993;13(5):312–320. Shad MU, Marsh C, Preskorn SH. The economic consequences of a drug–drug interaction. J Clin Psychopharmacol 2001; 21(1):119–120. Suchowersky O, deVries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry 1990;35(6):571–572. Toyama SC, Iacono RP. Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother 1994;28(3):405–406. Waters CH. Fluoxetine and selegiline: Lack of significant interaction. Can J Neurol Sci 1994;21(3):259–261. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study Group. Neurology 1997;48(4):1070–1077. Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry Suppl 1989(6): 38–45. Marangell LB. Switching antidepressants continued on page 247 Vol. 33 No. 4 • April 2008 • 27. 13. 28. 14. 29. 15. 30. 31. 32. REFERENCES 1. Thase ME. Therapeutic alternatives for difficult-to-treat depression: A narrative review of the state of the evidence. CNS Spectr 2004;9(11):808–816, 818–821. 2. Blackwell B, Marley E. Interactions of cheese and of its constituents with monoamine oxidase inhibitors. Br J Pharmacol Chemother 1966;26(1):120–141. 3. Nierenberg AA. Treatment choice after one antidepressant fails: A sur vey of northeastern psychiatrists. J Clin Psychiatry 1991;52(9):383–385. 4. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract 2004;10(4):239–248. 5. Nierenberg AA, Alpert JE, Pava J, et al. Course and treatment of atypical depression. J Clin Psychiatry 1998;59(Suppl 18): 5–9. 6. Davidson J RD, Pelton S. An outpatient evaluation of phenelzine and imipramine. J Clin Psychiatry 1987;48(4):143–146. 7. Liebowitz MR, Quitkin FM, Stewart JW, et al. Phenelzine v. imipramine in atypical depression: A preliminary report. Arch Gen Psychiatry 1984;41(7):669–677. 8. Liebowitz MR. Depression with anxiety and atypical depression. J Clin Psychiatry 1993;54(Suppl):10–14; discussion, 15. 9. Quitkin FM, Rothschild R, Stewart JW, et al. Atypical depression: Unipolar depressive subtype with preferential response to MAOIs. In: Kennedy SH, ed. Clinical Advances in Monoamine Oxidase Inhibitor Therapies. Washington, DC: American Psychiatric Press; 1994. 10. Janicak PG, Pandey GN, Davis JM, et al. Response of psychotic and nonpsychotic depression to phenelzine. Am J Psychiatry 1988;145(1):93–95. 11. Davidson JR, McLeod MN, Kurland AA, et al. Antidepressant drug therapy in psychotic depression. Br J Psychiatry 1977; 131:493–496. 12. Vallejo J, Gasto C, Catalan R, et al. Doubleblind study of imipramine versus phen17. 33. 18. 34. 19. 35. 36. 20. 37. 21. 22. 38. 23. 39. 40. 24. 41. 42. 25. 43. 26. 44. P&T® 219 http://www.bms.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.